Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash & Current Investments (2019 - 2025)

Historic Cash & Current Investments for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $645.9 million.

  • BridgeBio Pharma's Cash & Current Investments rose 5920.37% to $645.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $645.9 million, marking a year-over-year increase of 5920.37%. This contributed to the annual value of $681.1 million for FY2024, which is 5661.67% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Cash & Current Investments is $645.9 million, which was up 5920.37% from $756.9 million recorded in Q2 2025.
  • BridgeBio Pharma's Cash & Current Investments' 5-year high stood at $919.1 million during Q1 2021, with a 5-year trough of $352.9 million in Q2 2023.
  • Its 5-year average for Cash & Current Investments is $575.3 million, with a median of $547.4 million in 2024.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first plummeted by 4874.48% in 2023, then skyrocketed by 5920.37% in 2025.
  • BridgeBio Pharma's Cash & Current Investments (Quarter) stood at $393.9 million in 2021, then grew by 5.25% to $414.6 million in 2022, then increased by 4.89% to $434.9 million in 2023, then soared by 56.62% to $681.1 million in 2024, then dropped by 5.16% to $645.9 million in 2025.
  • Its last three reported values are $645.9 million in Q3 2025, $756.9 million for Q2 2025, and $540.6 million during Q1 2025.